Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | -1.38% | -3.91% | -20.69% |
Financials (USD)
Sales 2024 * | 223M | Sales 2025 * | 321M | Capitalization | 543M |
---|---|---|---|---|---|
Net income 2024 * | -281M | Net income 2025 * | -151M | EV / Sales 2024 * | 2.93 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 118M | EV / Sales 2025 * | 2.06 x |
P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-4.2
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -1.38% | ||
1 week | -3.91% | ||
Current month | -3.91% | ||
1 month | +8.03% | ||
3 months | -17.67% | ||
6 months | -17.48% | ||
Current year | -20.69% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 7.13 | -1.38% | 625,264 |
24-06-06 | 7.23 | -7.66% | 690,710 |
24-06-05 | 7.83 | +2.09% | 735,239 |
24-06-04 | 7.67 | -0.65% | 787,631 |
24-06-03 | 7.72 | +4.04% | 1,493,849 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.69% | 543M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.36% | 22.78B | |
-10.86% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- TVTX Stock